What is Pal-AHK?

Pal-AHK is a palmitoylated form of the tripeptide Ala-His-Lys used in cosmetic and hair-support discussions. Palmitoylation is intended to improve topical compatibility and skin or follicle delivery. [1][2]

The key public evidence comes from AHK and copper-complex hair-follicle biology rather than large finished-product clinical trials for every Pal-AHK cosmetic formula. [1][2]

Pal-AHK needs distinction from AHK-Cu, GHK-Cu, and Pal-GHK. Related copper-peptide biology can help explain plausibility, but each molecule and formulation has its own evidence limits. [1][2]

What Pal-AHK is investigated for

Pal-AHK evidence is grouped by practical use case and topical route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Hair growth and dermal papilla cell proliferation

Topical

34% Limited

Hair growth is the most direct Pal-AHK signal, but it remains in vitro and preclinical. [1]

Human evidence

Controlled topical Pal-AHK human hair-growth trials are not established in the cited literature. [1]

Animal / mechanistic evidence

In vitro human hair-growth work with a tripeptide-copper complex supports hair-follicle and dermal-papilla plausibility. [1]

Hair follicle cell survival signaling

Topical

28% Limited

Hair follicle survival is a lower-confidence mechanism within hair support. [1]

Human evidence

Human anti-apoptotic hair-follicle outcomes for Pal-AHK are not established in the cited literature. [1]

Animal / mechanistic evidence

Cell-survival discussion is inferred from the same in vitro hair-follicle biology rather than independent clinical outcomes. [1]

Skin appearance and collagen claims

Topical

18% Insufficient

Skin appearance claims remain insufficient until direct Pal-AHK skin data are available. [1][2]

Human evidence

Controlled Pal-AHK skin appearance, collagen, pigmentation, or microcirculation trials are not established in the cited literature. [1][2]

Animal / mechanistic evidence

The cited literature is stronger for hair-follicle in vitro biology than for skin collagen or tone outcomes. [1][2]

Evidence snapshot

Overall confidence

Limited

34%

Pal-AHK remains a preclinical-to-ex vivo cosmetic and hair-follicle rationale. Controlled finished-product scalp and skin outcomes remain limited. [1]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

24%

Human evidence

Limited

Human ex vivo hair-follicle work supports AHK-related plausibility, but controlled finished-product outcomes are limited. [1]

24%

Animal / preclinical

Limited

Dermal papilla and follicle biology support the scalp rationale. [1]

34%

Mechanism support

Limited

AHK-related tripeptide research links hair-follicle elongation, dermal papilla activity, and matrix signaling with scalp-support rationale. Palmitoylation is intended to make the peptide more formulation-friendly. [1]

Forms & administration

Pal-AHK is tracked as a topical cosmetic peptide ingredient for scalp and skin products. Its protocol context stays topical and formulation-specific rather than systemic. [2][1]

Topical

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Topical amounts depend on the finished product. [2][1]

Frequency

Usually applied once or twice daily. [2][1]

Timing Considerations

Apply in the morning or evening. [2][1]

Cycle Length

Track skin or scalp results for several months. [2][1]

What to expect

First week

Topical Pal-AHK may change scalp or skin feel, surface smoothness, hydration, and comfort as the routine settles in. [1][2]

Weeks 8-12

Topical scalp or skin use may show changes in shedding, part-line appearance, texture, and skin smoothness in baseline photos. [1][2]

After stopping

Surface cosmetic effects may fade after topical Pal-AHK stops, and hair-cycle changes may drift gradually. [1][2]

Safety profile

Pal-AHK safety is mainly topical cosmetic tolerability: scalp sensitivity, irritation, dryness, formula concentration, and combinations with other actives matter. [1][2]

Common side effects

Redness / irritation [1][2]
Scalp itch [1][2]
Dryness [1][2]

Cautions

Sensitive scalp [1][2]
Broken / infected skin [1][2]
Copper-peptide overlap [1][2]
Pregnancy review [1][2]

What we don't know

Finished-formula concentration, delivery vehicle, copper-peptide overlap, and long-term scalp use are not standardized across products. [1][2]

Who Pal-AHK is not for

Route-specific avoid and medical-review notes:

Broken or infected scalp
Broken or infected scalp warrants medical review or avoidance for Pal-AHK. [1][2]
Known allergy to formula components
Known allergy to formula components warrants medical review or avoidance for Pal-AHK. [1][2]
Severe dermatitis flare without clinician review
Severe dermatitis flare without clinician review warrants medical review or avoidance for Pal-AHK. [1][2]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

Retinoids / acids / exfoliants
Retinoids, AHAs, BHAs, scrubs, or irritating scalp actives can compound redness, burning, and barrier disruption; this is a route-specific caution. [1][2]
Other copper peptides
GHK-Cu, AHK-Cu, or multiple copper-peptide products can add copper-burden and irritation uncertainty; this is a product-quality caution. [1][2]
Minoxidil / topical hair products
Minoxidil, alcohol-heavy vehicles, or leave-on hair actives can compound scalp dryness, itch, or irritation; this is a route-specific caution. [1][2]

Regulatory status

United States

In the U.S. as of 2026-06-21, Pal-AHK may appear in cosmetic-style topical products, but hair-growth or therapeutic claims are drug claims and are not FDA-approved. Cosmetic availability is not the same as drug approval. [2][3][6][7]

Route	FDA drug approval	503A compounding
Topical	Not Approved Pal-AHK is not FDA-approved as a topical drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [2][3][6][7]	Not Listed Pal-AHK is not in the current reviewed 503A compounding bucket for the topical route; compounding status is separate from FDA drug approval. [2][3][6][7]

Topical

FDA drug approval

Not Approved

Pal-AHK is not FDA-approved as a topical drug in the U.S. for the reviewed use; research-market supply and compounding are separate from FDA approval. [2][3][6][7]

503A compounding

Not Listed

Pal-AHK is not in the current reviewed 503A compounding bucket for the topical route; compounding status is separate from FDA drug approval. [2][3][6][7]

International

EU/Europe, UK, Canada, and Australia separate cosmetic products from therapeutic claims. Topical cosmetic availability can follow cosmetic or industrial-chemical frameworks, while hair-growth, skin-lightening, injectable, oral, or disease-treatment claims need market-specific therapeutic-product review. [9][10][11][12][5][13][14][15][16]

Sports & competition

WADA has no specific issue for topical cosmetic Pal-AHK in the reviewed materials; S0 is mainly relevant if a product is used as a non-approved systemic pharmacological substance. [4][2][3][6][7]

How it works

Pal-AHK is built around an AHK-related tripeptide signal linked with hair-follicle elongation, dermal papilla activity, and extracellular-matrix signaling. In plain terms, the proposed cosmetic mechanism is local scalp or skin support. [1]

Topical delivery is the evidence boundary. Palmitoylation is meant to make the peptide more formulation-friendly, but a serum can only support a local cosmetic claim if the molecule reaches the target tissue at a concentration that matches the evidence. That keeps the mechanism local, cosmetic, and formulation-dependent rather than systemic. [1]

Research gaps & open questions

What the current literature has not yet settled about Pal-AHK:

Controlled trials need to test finished Pal-AHK scalp products in people and measure hair shedding, density, thickness, and growth. [1]

Studies should compare concentrations and delivery systems to show how much Pal-AHK reaches the hair follicle and which formulas work best. [1]

Combination studies need to show whether Pal-AHK can be safely used with minoxidil, retinoids, or other scalp actives and whether it adds benefit. [1]

Common questions

Is Pal-AHK a copper peptide?

No. Pal-AHK is an AHK-derived cosmetic peptide discussed near copper-peptide biology, but exact complex and formula matter. [2][3][1]

Is Pal-AHK FDA-approved for hair growth?

No. Pal-AHK is not FDA-approved in the U.S. as a hair-growth drug; cosmetic topical use is regulated separately from therapeutic claims. [2][3][1]

Is Pal-AHK the same as GHK-Cu?

No. They are related cosmetic-peptide concepts, but they have different sequences, delivery assumptions, and evidence. [2][3][1]

Myths & misconceptions

Myth

A Pal-AHK serum is a hair-regrowth drug.

Reality

Topical cosmetic support is not the same as an approved alopecia treatment. [1]

Myth

More copper peptides are always better.

Reality

Stacking similar actives can increase irritation and make results harder to interpret. [1]

History & discovery

Pal-AHK grew from cosmetic peptide attempts to adapt short hair- and matrix-related sequences for topical products. Its history is formulation-led, not systemic drug development. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty. [1][2]

Human hair-follicle work on an AHK/copper-related tripeptide complex gave the family a scalp-support rationale. That evidence remains local and experimental rather than a drug approval path. [1][2]

Palmitoylation made AHK-style peptides more product-friendly for serums and cosmetic formulas. That shifted interpretation toward topical delivery, concentration, and vehicle rather than injectable outcomes. [1][2]

Published research 4 studies

[1]

The effect of tripeptide-copper complex on human hair growth in vitro.

Arch Pharm Res, 2007 Jul. in vitro.

[2]

Drugs@FDA/openFDA query for Pal-AHK

U.S. Food and Drug Administration. database query.

[3]

Compounding and the FDA: Questions and Answers

U.S. Food and Drug Administration. official guidance.

[4]

The 2026 List of Prohibited Substances and Methods

World Anti-Doping Agency. regulatory.